-
Pediatrics Dec 2021Despite a >99% reduction in US mumps cases after the introduction of mumps vaccine in 1967, outbreaks have occurred in schools and other settings involving vaccinated...
BACKGROUND
Despite a >99% reduction in US mumps cases after the introduction of mumps vaccine in 1967, outbreaks have occurred in schools and other settings involving vaccinated children and adolescents since 2006.
METHODS
We analyzed mumps cases reported by US health departments to the National Notifiable Diseases Surveillance System. We present the incidence and vaccination status of pediatric cases (age <18 years) during 2007-2019 and describe demographic, clinical, and vaccination characteristics of pediatric cases reported during the most recent resurgence in 2015-2019.
RESULTS
During 2007-2019, 9172 pediatric cases were reported, accounting for a median of 32% of all cases reported each year (range: 13%-59%). A median of 87% (range: 81%-94%) of pediatric patients each year had previously received ≥1 measles, mumps, and rubella (MMR) vaccine dose. During 2015-2019, of 5461 pediatric cases reported, only 2% of those with known import status (74%) were associated with international travel. One percent of patients had complications and 2% were hospitalized. Among patients aged ≥1 year with known vaccination status (72%), 74% of 1- to 4-year-olds had received ≥1 MMR dose and 86% of 5- to 17-year-olds had received ≥2 MMR doses. Since 2016, pediatric mumps cases have been reported in most US states each year (range: 38-45 states).
CONCLUSIONS
Since 2007, one-third of US reported mumps cases occurred in children and adolescents, the majority of whom were vaccinated. Clinicians should suspect mumps in patients with parotitis or mumps complications, regardless of age, travel history, and vaccination status.
Topics: Adolescent; Age Distribution; Child; Child, Preschool; Disease Outbreaks; Female; Hospitalization; Humans; Immunization, Secondary; Incidence; Infant; Male; Measles-Mumps-Rubella Vaccine; Mumps; Sex Distribution; Time Factors; Travel-Related Illness; United States; Vaccination Coverage
PubMed: 34814181
DOI: 10.1542/peds.2021-051873 -
Przeglad Epidemiologiczny 2021Mumps is a highly infectious viral disease, the source of infection is an infected person. In 2003, compulsory vaccination against mumps was introduced in Poland,...
BACKGROUND
Mumps is a highly infectious viral disease, the source of infection is an infected person. In 2003, compulsory vaccination against mumps was introduced in Poland, carried out according to a two-dose schedule. The combined MMR vaccine (against measles, mumps and rubella) is used as part of the Protective Vaccination Program (PVP). Mumps vaccination has led to a significant reduction in the incidence of mumps in Poland.
AIM
The aim of the study was to evaluate the epidemiological indicators of mumps in Poland in 2019 compared to previous years.
METHODS
The analysis of the epidemiological situation of mumps in Poland in 2019 was based on the interpretation of data from the bulletin "Infectious diseases and poisonings in Poland in 2019" and "Vaccinations in Poland in 2019".
RESULTS
In 2019, 1,338 mumps cases were registered in Poland. The total incidence was 3.5 per 100,000 inhabitants and was lower compared to 2018. The highest incidence 4.6 per 100,000 inhabitants were registered in the Opolskie Voivodeship and the lowest - 2.5 in the Podkarpackie Voivodeship. The incidence was the highest among 6-year-olds and amounted to 32.3/100,000. Comparing the differences between the sexes, the incidence of men (4.1/100,000) was higher than that of women (2.9). In 2019, 22 patients were hospitalized due to mumps in Poland, which was less than in 2018 (28). The level of mumps vaccination in children at 3 years of age was lower by 0.3% compared to 2018 and amounted to 92.6% in Poland.
CONCLUSIONS
Maintaining a high percentage of children vaccinated against mumps will provide sustaining decline in cases of mumps in the coming years.
Topics: Age Distribution; Child; Female; Humans; Incidence; Infant; Male; Mass Vaccination; Measles-Mumps-Rubella Vaccine; Mumps; Poland; Rubella; Rural Population; Urban Population
PubMed: 34696560
DOI: 10.32394/pe.75.21 -
Przeglad Epidemiologiczny 2022Mumps is an acute, generalized viral disease whose source of infection is the infected person. In 2003, vaccination against mumps became compulsory in Poland, performed...
INTRODUCTION
Mumps is an acute, generalized viral disease whose source of infection is the infected person. In 2003, vaccination against mumps became compulsory in Poland, performed according to a twodose scheme. The combined MMR vaccine (against measles, mumps and rubella) was introduced as part of the Protective Vaccination Program (PVP), which influenced the number of cases in Poland.
AIM
The aim of the study was to evaluate the epidemiological indicators of mumps in Poland in 2020 compared to previous years.
METHODS
The analysis of the epidemiological situation of mumps in Poland in 2020 was based on the interpretation of data from the bulletin "Infectious diseases and poisonings in Poland in 2020" and "Vaccinations in Poland in 2020".
RESULTS
In 2020, 582 cases of mumps were registered in Poland. The total incidence was 1.5 per 100,000 inhabitants and was lower compared to 2019. The highest incidence was 2.0 per 100,000 inhabitants were registered in the Świętokrzyskie Voivodeship and the lowest - 0.7 in the Dolnośląskie Voivodeship. The highest incidence (24.6/100,000) was recorded in children aged 5-9 years. The incidence of men (1.8/100,000) was higher than that of women (1.2/100,000). In 2020, 6 patients were hospitalized in Poland due to mumps, which was less than in 2019 (22 patients). The level of vaccination against mumps in children aged 3 was lower by 0.7 percentage points compared to 2019 and amounted to 91.9% across Poland.
CONCLUSIONS
In 2020, there was a decrease in the number of mumps cases compared to the previous year. The lower incidence may have been the result of a reduction in mumps virus transmission due to a change in population health behavior during the COVID-19 pandemic. Due to the epidemiological threat, the functioning of nurseries, kindergartens and schools was also temporarily suspended, which resulted in a reduction in the incidence of mumps in younger age groups, which are the main group of patients.
Topics: Child; Male; Humans; Female; Infant; Mumps; Poland; Pandemics; Mass Vaccination; Rural Population; Urban Population; Age Distribution; COVID-19; Measles-Mumps-Rubella Vaccine; Incidence
PubMed: 37017448
DOI: 10.32394/pe.76.51 -
Postgraduate Medicine Nov 2019
Topics: Anti-Vaccination Movement; Humans; Measles; Measles-Mumps-Rubella Vaccine; Vaccination Refusal
PubMed: 31554447
DOI: 10.1080/00325481.2019.1669409 -
Viruses Jun 2022The resurgence of mumps in vaccinated adult populations has raised concerns about possible waning vaccine immunity or a potential lack of protection to the circulating... (Review)
Review
The resurgence of mumps in vaccinated adult populations has raised concerns about possible waning vaccine immunity or a potential lack of protection to the circulating strain. A number of individual studies have investigated if there are amino acid variations between the circulating wild-type strains and vaccine strains. In these studies, the HN and F mumps surface glycoproteins have been of interest, because of their role in viral infection, and because the HN protein is the target of neutralizing antibodies. Here, we summarize the single nucleotide variants and their potential effect that have been identified between mumps genotypes in the HN and F proteins.
Topics: Antibodies, Neutralizing; Glycoproteins; HN Protein; Humans; Mumps; Mumps virus
PubMed: 35746805
DOI: 10.3390/v14061335 -
Frontiers in Microbiology 2020Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global... (Review)
Review
Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the rise, including in populations with high vaccination coverage. Several epidemiological studies suggest that this infectious virus continues to be a worldwide public health threat. The development and deployment of an improved, prophylactic mumps vaccine that provides long-lasting protection is indeed a priority. The purpose of this review is to provide an immuno-biological perspective on mumps vaccines. Here, we review the virology of mumps, licensed mumps vaccines, and the typical immune responses elicited following mumps vaccination. Furthermore, we discuss the limitations and challenges of the currently licensed mumps vaccines and provide strategies for the development of an improved mumps vaccine.
PubMed: 32973721
DOI: 10.3389/fmicb.2020.01999 -
JAAPA : Official Journal of the... Dec 2021
Topics: Drug Combinations; Humans; Infant; Measles; Mumps; Rubella; Vaccination
PubMed: 34813536
DOI: 10.1097/01.JAA.0000800280.14011.81 -
Transplant Infectious Disease : An... Apr 2023Revaccination program after HCT is necessary due to the loss of lifelong immunity acquired by previous vaccination or infections. The program is complex and even in a...
Revaccination program after HCT is necessary due to the loss of lifelong immunity acquired by previous vaccination or infections. The program is complex and even in a favourable scenario, it takes more than 2 years to be completed. As the complexity of HCT increases (alternative donors, diversity of monoclonal antibodies), studies evaluating the response to vaccination in this population are welcome, especially those that evaluate live attenuated vaccines given their scarcity. Furthermore, measles, mumps, rubella and even yellow fever, and poliomyelitis outbreaks have perplexed infectious diseases clinicians and epidemiologists globally, most of them due to the decline in vaccination coverage rates in children and adults, because of the growth of antivaccine movements around the world. The study of Lin et al. adds important information about measles, mumps and rubella vaccination after HCT.
Topics: Child; Humans; Infant; Viral Vaccines; Measles-Mumps-Rubella Vaccine; Mumps; Vaccines, Attenuated; Vaccines, Combined; Measles; Rubella; Vaccination; Antibodies, Viral
PubMed: 36864672
DOI: 10.1111/tid.14044 -
Scandinavian Journal of Immunology Jun 2023Measles, mumps and rubella (MMR) are contagious infectious diseases that can be prevented by immunization. However, MMR infections can occur in previously immunized... (Review)
Review
Measles, mumps and rubella (MMR) are contagious infectious diseases that can be prevented by immunization. However, MMR infections can occur in previously immunized individuals. The vaccine response is, among other factors, influenced by the combined effects of many genes. This systematic review investigates the genetic influence on measles, mumps and rubella antibody responses after childhood vaccination. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), systematic literature searches were conducted in the medical databases PubMed, EMBASE and PsycINFO. Search strings were adjusted for each database. Citations were included if they measured and compared the immune response with immunogenetics after vaccination with a vaccine containing one or more of the following components: measles, mumps and/or rubella, MMR. The measure of vaccine response studied was antibodies after vaccination. Forty-eight articles were included in the final analysis. The results suggest that genetic determinants, including host genes, and single nucleotide polymorphisms in immune-related genes influence the MMR antibody responses after vaccination. Specifically, replicated associations were found between HLA, CD46, RARB, IRF9, EIF2AK2, cytokine genes and MMR vaccine-induced humoral immune responses. This knowledge can be useful in understanding and predicting immune responses and may have implications for future vaccine strategies.
Topics: Humans; Adolescent; Infant; Mumps; Measles-Mumps-Rubella Vaccine; Rubella; Measles; Antibodies, Viral
PubMed: 38157324
DOI: 10.1111/sji.13266 -
Vaccine Apr 2023This paper reviews the administration related to vaccination in Japan after the enactment of the Immunization Act in 1948, under which vaccination was implemented... (Review)
Review
This paper reviews the administration related to vaccination in Japan after the enactment of the Immunization Act in 1948, under which vaccination was implemented mandatory for the public. To enhance the effectiveness of vaccination activities, the government implemented group vaccination, which is convenient for vaccinating recipients all at once. In 1976, Japan established the relief system for health damage after vaccination. While some projects, such as the mass administration of live oral polio vaccine in 1961, achieved excellent results, incidents leading to health damage occurred, such as the diphtheria toxoid immunization incident (1948) and frequent occurrence of aseptic meningitis owing to the measles, mumps, and rubella vaccine (1989). In December 1992, the Tokyo High Court sentenced that the onset of health damage after vaccination could be attributed to the negligence of the national government. In the revision of the Immunization Act in 1994, the "mandatory vaccination" enforced until then was changed to "recommended vaccination." The Act was also changed to recommend "individual vaccination" in principle, which is performed after primary care physicians investigate the physical condition of individual recipients and carefully conduct preliminary examination. For approximately 20 years from the 1990s, a vaccine gap existed between Japan and other countries. From around 2010, efforts have been made to bridge this gap and establish the global standard in vaccination.
Topics: Humans; Japan; Rubella Vaccine; Vaccination; Mumps Vaccine; Measles Vaccine; Measles; Mumps; Measles-Mumps-Rubella Vaccine; Rubella
PubMed: 36933981
DOI: 10.1016/j.vaccine.2023.03.020